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Two more words regarding clinical trials: 
deception/truth, the moral anemia of Big Pharma
Dos palabras más sobre ensayos clínicos: 
engaño/verdad, la anemia moral de la "Big Pharma"
In his condition of moral agent, how can any
given person at any given time activate, to his
own benefit and with a certain possibility of
success, the abundant and powerful resources
capable of producing good conscience? It is as if
an unconditional rule were applied to exonerate
from blame, a perverse law that states: act in
such a way as that the maxim of your acts shall
be to not feel guilty, no matter what you do. 
Rafael A. Herra. Autoengaño: Palabras para todos
y sobre cada cual (1)
One sometimes finds oneself reading
articles that cause great satisfaction in their
readers, even when they – or perhaps it is
because they – seem to present more questions
than answers. The article written by Dr. Antonio
Ugalde and Dr. Núria Homedes (2) is without a
doubt one of these types of articles. 
The authors’ initial assertion that “the
covering up of ethical violations, errors, and even
fraud is a tacit condition imposed by the industry
in order to continue future clinical trials (2)” may
at first glance seem a bit hyperbolic; it inevitably
leads us to question and reflect upon its veracity.
Is that really how it is? Is it true that
pharmaceutical companies are so lacking in
ethics and morality that they conceal errors
committed during clinical trials and foster acts of
fraud?
When we see that those involved in the
implementation of clinical trials in Latin American
countries (the employees of the pharmaceutical
companies as well as their complicit counterparts,
those who without a trace of shame present
themselves in the public eye as “clinical
researchers”) continue to demonstrate behaviors
that indicate a systematic lack of ethics and an
increasing contempt for the most basic principles of
morality and human decency, we have no choice
but to continue along this path of analysis and
reflection. In the chorus of voices worldwide that
have that have spoken out with serious, well-
founded, objective and courageous criticisms
concerning the activities of the pharmaceutical
industry, there is no doubt that Antonio Ugalde and
Núria Homedes stand out alongside such well-
known names as Marcia Angell, John Abramson
and Jerry Avorn from the English-speaking world;
as well as Miguel Jara and Juan Gérvas, to mention
just two names that come to mind from the
Spanish-speaking world. But in order to move away
from simple words of praise and admiration for the
validity, relevance and pertinence of the arguments
presented by Ugalde and Homedes, I would like to
contribute some ideas that may serve as a
complement to the debate at hand, centered on the
“two more words” referred to in the title of this
commentary, whose meanings are also conceived
of dichotomously: deception and truth. 
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I would like to make reference to the
overt deception with which pharmaceutical
companies attempt to subjugate the medical
profession, other health professionals, the ethics
committees in charge of reviewing and approving
the study protocols, and even the patients
themselves, every time these companies express
to the so-called researchers and the regulatory
agencies “the need” to carry out “another type”
of clinical studies. They refer to studies that go
beyond those required of companies in order to
obtain authorization to market their products.
These “post-commercialization” studies, known
as Phase Iv studies, should in principle be
subject to priorities concerning patient safety,
such as searching for adverse effects of particular
interest which were not clearly detected during
the development phases. These studies are
justifiable only when safety issues are involved
and should be proposed only when the
regulatory agencies or local health authorities
consider it pertinent to carry out such studies.
The protocols of these studies are of
poor scientific quality; written by medical
marketing managers (usually physicians with
more experience and training in business
administration than in clinical medicine), their
sole purpose is to support the business of the
pharmaceutical industry. Most of these protocols
are hybrid documents composed of information
from other studies, with minimal changes when
not explicitly copied from studies already
conducted. With slight variations in their titles or
in their basic designs, these “new protocols” are
mere “exercises” of global marketing and
promotion strategies. Their one and only purpose
is to familiarize doctors identified as “potential
prescribers” with the use of new drugs.
According to the English terminology, these
protocols are “designed” to provide “hands-on
experience” to the so-called KOLs, “key opinion
leaders” within the field in which the protocol
will be carried out. The KOLs are specialized
physicians the pharmaceutical companies have
clearly classified within a “ranking” of relative
importance in terms of the usefulness, the
contribution and the special retributions by
which those physicians safeguard the companies’
interests, collaborating as lecturers, “authors” of
the articles, potential “researchers,” or simply,
thanks to their reputation as well-known
physicians who consistently prescribe the
products of the company.
Frequently, the industry attempts to
hide fact that these studies belong to Phase Iv
trials, instead classifying them with the dubious
nomenclature of Phase III B studies so that they
still appear to be development trials. The
authorities responsible for enforcing ethical
regulations and for approving research protocols
in Latin American countries are not as organized
as one would wish them to be. They also lack
personnel capable of detecting the serious
methodological flaws these protocols contain or
of recognizing objectives that are not genuine to
a Phase Iv study. 
Among those who work in the
implementation of clinical trials persists the
discourse that clinical trials do not just mean a
benefit for trial participants, but for many
participants represent the only resource at hand
with which they may save their lives if they are
suffering from a serious disease. Many
professionals working for these companies have
unconsciously developed mechanisms with
which justify and excuse what they do in their
jobs to themselves and to others. These
individuals have a perception of what they do that
is adapted so fully to their wishes and valued so
closely in line with their personal interests, that it
is hard to believe that their convictions are the
product of their cynicism. This is something that
escapes the understanding of any person with a
minimum ability for analysis and reflection. But
also there are people who do not deceive
themselves: they know they are lying and they do
it for a specific personal goal. This is why they
consciously scorn and underestimate the few
genuine pieces of information that can be derived
from clinical trials and instead become architects
of all types of marketing schemes. Ironically, these
individuals occupy decision-making roles and are
admired by their company peers for the acuity
and efficacy of their business acumen. It is these
scrupless individuals, usually medical managers
or managers of business units, who make use of
clinical trials findings (only the positive results, of
course, because negative results are never
published) to provide fraudulent explanations of
pharmacological or physiopathological processes.
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It is a severe offense against the authentic
scientific spirit that these individuals take
advantage of many health care professionals’
desire for knowledge in order to instill and convey
false information, concealing true facts or only
partially expressing them and distorting concepts
in order to obtain some sort of competitive
advantage for themselves or for the company that
employs them.
As long as money continues to be the
primary incentive for the executives that work in
pharmaceutical companies, there is very little
hope they will one day make the altruistic and
effective contributions they so claim to. As long
as the unethical and amoral behaviors prevail
over all others, no discourse of political
correctness and sensitivity to the health needs of
the population will redress the unpopularity
these companies have gained. If, by chance,
pharmaceutical industry executives were able to
prioritize truth over deception, and tried to be
honest with themselves and stop deceiving
themselves with trite and sentimental slogans
(“We work for your health,” “We innovate for
your well-being,” “Your family’s health is our
reason for being,” among others), they would
have to admit, at least, that veracity is
incompatible with the practices of corporations
whose main responsibility lies in maximizing
their shareholders’ profits, regardless of whether
the company’s activities satisfy a genuine health
need. It is hard to believe that an industry that
chooses to dedicate itself to the development of
so-called “blockbuster” drugs for chronic
diseases, and to what are now called “lifestyle”
drugs for the treatment of baldness, obesity,
shyness, erectile dysfunction, or to lengthen
eyelashes and make nails more beautiful, can
attain even a minimum of credibility, while
millions of people in underdeveloped countries
die as a result of the scant or nonexistent interest
these companies show in developing drugs for
the treatment of serious (but “forgotten”) diseases
that affect large populations from countries
lacking a market able to afford  such drugs.
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